See who owns your news

Published 2 days ago • loading... • Updated 2 days ago

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

Summary by Watauga Democrat

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

32 Articles

32 Articles

+31 Reposted by 31 other sources

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –

2 days ago·Pennsylvania, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources32

Leaning Left3Leaning Right2Center22Last Updated19 hours agoBias Distribution

82% Center

Bias Distribution

82% of the sources are Center

82% Center

+17

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in Chicago, United States 2 days ago on Tuesday, October 6, 2026.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics